[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malignant-brain-glioma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malignant-brain-glioma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100432253","spectroscopic-mri-guided-proton-therapy-in-assessing-metabolic-change-in-pediatric-patients-with-brain-tumors-100432253",false,"NCT04908709","Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients With Brain Tumors","Spectroscopic MRI Guided Proton Therapy for Pediatric High-Grade Glioma (RAD4500)","Inclusion Criteria:\n\n* Pathologically diagnosed high-grade glioma (World Health Organization \\[WHO\\] grade 3-4). Patients with a radiographically diagnosed high-grade glioma may enroll prior to pathologic confirmation, but would be removed from study if pathology did not confirm the diagnosis of high-grade glioma.\n* Primary tumor located within the supratentorial brain.\n* Recommended to receive definitive radiation therapy.\n* Able to receive MRI scans.\n* Both males and females, and members of all races and ethnic groups are eligible for this trial.\n\nExclusion Criteria:\n\n* Patients with pacemakers, non-titanium aneurysm clips, neurostimulators, cochlear implants, non-titanium metal in ocular structures, or other incompatible implants which makes MRI safety an issue are excluded.\n* Patients that have any significant medical illnesses that in the investigator's opinion cannot be adequately tolerate MRI scan are excluded.\n* Pathology demonstrated low-grade glioma or other benign or non-invasive brain tumor.","ALL","21 Years",{"count":19,"type":20},25,"ESTIMATED","INTERVENTIONAL",[23],"NA","This trial studies how well spectroscopic magnetic resonance imaging (MRI) guided proton therapy works in assessing metabolic change in pediatric patients with brain tumors. The non-invasive imaging, such as spectroscopic MRI may help to map the differences in tumor metabolism compared to healthy tissue without injection of any contrast agent.",[26],"Malignant Brain Glioma","RECRUITING","2026-03-02",{"date":30,"type":31},"2026-03-04","ACTUAL",{"date":33,"type":31},"2018-12-20",{"date":35,"type":20},"2030-10-13",{"name":37,"class":38},"Emory University","OTHER",3,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100526280","phase-2-post-operative-dosing-of-dexamethasone-in-patients-with-brain-tumors-after-a-craniotomy-pods-trial-100526280","NCT06132685","Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial","Post-Operative Dosing of Steroids Post Craniotomy for Brain Tumor (PODS)","Inclusion Criteria:\n\n* Patients with radiographic findings consistent with either HGG, LGG, Meningioma, or brain metastasis\n* Age equal to or above 18\n\nExclusion Criteria:\n\n* Known hypothalamic-pituitary-adrenal (HPA) axis dysfunction\n* Tumor causing compression of the sella or pituitary dysfunction\n* Known immunodeficiency - including but not limited to severe combined immunodeficiency (SCID), common variable immunodeficiency (CVID), lymphocytopenia\n* Taking immunosuppressive drugs - including but not limited to methotrexate, mycophenolate, rapamycin, tacrolimus, adalimumab, infliximab. Greater than two weeks of recent daily corticosteroid use or the use of corticosteroids equivalent to \\> 85 mg of dexamethasone in the last month\n* Current lymphoma or leukemia\n* History of solid organ transplant\n* Minors \\\u003C 18\n* Pregnant women\n* History of cerebrovascular accident leading to neurologic deficit","18 Years",{"count":49,"type":20},200,[51],"PHASE2","This phase II trial tests the effect of decreasing (tapering) doses of dexamethasone on steroid side effects in patients after surgery to remove (craniotomy) a brain tumor. Steroids are the gold standard post-surgery treatment to reduce swelling (edema) at the surgical site to reduce neurological symptoms. Although, corticosteroids reduce edema, they have side effects including high blood sugar, high blood pressure, and can impair wound healing. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response. It also works to treat other conditions by reducing swelling and redness. Tapering doses dexamethasone may decrease steroid side effects without increasing the risk of edema in patients with brain tumors after a craniotomy.",[54,26,55,56],"Low Grade Glioma","Malignant Brain Neoplasm","Meningioma","2026-02-06",{"date":59,"type":31},"2026-02-10",{"date":61,"type":31},"2025-01-09",{"date":63,"type":20},"2028-07-30",{"name":37,"class":38},1]